Comparison of Topical and Intravenous Administration of WIN 55-212-2 in Normotensive Rabbits

REFERENCES

• Zhang Y, Gao Q, Duan S, et al. Upregulation of Copine1 in trabecular meshwork cells of POAG patients: A membrane proteomics approach. Mol Vis 2008; 14: 1028–1036
   PubMed Web of Science ®Google Scholar
• Chauhan B C. Endothelin and its potential role in glaucoma. Can J Ophthalmol 2008; 43: 356–360
   PubMedGoogle Scholar
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487–497
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000; 130: 429–440
   PubMed Web of Science ®Google Scholar
• Sofia R D, Kubena R K, Barry H, III. Comparison among four vehicles and four routes for administering Δ 9-tetrahydrocannabinol. J Pharm Sci 1974; 63: 939–941
   PubMedGoogle Scholar
• Green K, Roth M. Ocular effects of topical administration of Δ 9-tetrahydrocannabinol in man. Arch Ophthalmol 1982; 100: 265–267
   PubMed Web of Science ®Google Scholar
• Juntunen J, Jarvinen T, Niemi R. In vitro corneal permeation of cannabinoids and their water-soluble phosphate ester prodrugs. J Pharm Pharmacol 2005; 57: 1153–1157
   PubMed Web of Science ®Google Scholar
• Pate D W, Jarvinen K, Urtti A, Mahadevan V, Jarvinen T. Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci 1998; 63: 2181–2188
   PubMed Web of Science ®Google Scholar
• Kearse E C, Green K. Effect of vehicle upon in vitro transcorneal permeability and intracorneal content of Δ 9-tetrahydrocannabinol. Curr Eye Res 2000; 20: 496–501
   PubMed Web of Science ®Google Scholar
• Green K E, Kearse C E. Ocular penetration of topical Δ 9-tetrahydrocannabinol from rabbit corneal or cul-de-sac application site. Curr Eye Res 2000; 21: 566–570
   PubMedGoogle Scholar
• Valiveti S, Hammell D C, Earles D C, Stinchcomb A L. Transdermal delivery of the synthetic cannabinoid WIN 55-212-2: In vitro/in vivo correlation. Pharm Res 2004; 21: 1137–1145
   PubMed Web of Science ®Google Scholar
• Green K, Bigger J F, Kim K, Bowman K. Cannabinoid penetration and chronic effects in the eye. Exp Eye Res 1977; 24: 197–205
   PubMed Web of Science ®Google Scholar
• Green K, Wynn H, Bowman K A. A comparison of topical cannabinoids on intraocular pressure. Exp Eye Res 1978; 27: 239–246
   PubMed Web of Science ®Google Scholar
• Merritt J C, Perry D D, Russell D N, Jones B F. Topical Δ 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J Clin Pharmacol 1981; 21: 467S–471S
   PubMed Web of Science ®Google Scholar
• Colasanti B K, Craig C R, Allara R D. Intraocular pressure, ocular toxicity, and neurotoxicity after administration of cannabinol or cannabigerol. Exp Eye Res 1984; 39: 251–259
   PubMed Web of Science ®Google Scholar
• Muchtar S, Almog S, Torracca M T, Saettone M F, Benita S. A submicron emulsion as ocular vehicle for Δ 8-tetrahydrocannabinol: Effect on intraocular pressure in rabbits. Ophthalmic Res 1992; 24: 142–149
   PubMed Web of Science ®Google Scholar
• Friedenwald J S, Buschke W. Some factors concerned in the mitotic and wound-healing activities of the corneal epithelium. Trans Am Ophthalmol Soc 1944; 42: 371–383
   PubMedGoogle Scholar
• Samudre S S, Lattanzio F A, Jr, Williams P B, Sheppard J D, Jr. Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther 2004; 20: 533–547
   PubMed Web of Science ®Google Scholar
• Hepler R S, Frank I R. Marihuana smoking and intraocular pressure. JAMA 1971; 217: 1392
   PubMed Web of Science ®Google Scholar
• Wilson D M, Peart J, Martin B R, Bridgen D T, Byron P R, Lichtman A H. Physiochemical and pharmacological characterization of a Δ 9-THC aerosol generated by a metered dose inhaler. Drug Alcohol Depend 2002; 67: 259–267
   PubMed Web of Science ®Google Scholar
• Korczyn A D, Eshel Y. Mydriasis induced by tetrahydrocannabinol (THC) in rats. Invest Ophthalmol Vis Sci 1982; 22: 408–410
   PubMedGoogle Scholar
• Valiveti S, Hammell D C, Earles D C, Stinchcomb A L. In vitro/in vivo correlation studies for transdermal Δ 8-THC development. J Pharm Sci 2004; 93: 1154–1164
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Lindgren J E, Wahlen A, Agurell S, Hollister L E, Gillespie H K. Plasma Δ 9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980; 28: 409–416
   PubMed Web of Science ®Google Scholar
• Tomida I, Pertwee R G, Azuara-Blanco A. Cannabinoids and glaucoma. Br J Ophthalmol 2004; 88: 708–713
   PubMed Web of Science ®Google Scholar
• Mannila J, Jarvinen T, Jarvinen K, Tervonen J, Jarho P. Sublingual administration of Δ 9-tetrahydrocannabinol/beta-cyclodextrin complex increases the bioavailability of Δ 9-tetrahydrocannabinol in rabbits. Life Sci 2006; 78: 1911–1914
   PubMed Web of Science ®Google Scholar
• Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee R G, Robson P J. Effect of sublingual application of cannabinoids on intraocular pressure: A pilot study. J Glaucoma 2006; 15: 349–353
   PubMed Web of Science ®Google Scholar
• Brenneisen R, Egli A, Elsohly M A, Henn V, Spiess Y. The effect of orally and rectally administered Δ 9-tetrahydrocannabinol on spasticity: A pilot study with 2 patients. Int J Clin Pharmacol Ther 1996; 34: 446–452
   PubMed Web of Science ®Google Scholar
• Perlin E, Smith C G, Nichols A I, et al. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. J Pharm Sci 1985; 74: 171–174
   PubMed Web of Science ®Google Scholar
• Jarho P, Pate D W, Brenneisen R, Jarvinen T. Hydroxypropyl-beta-cyclodextrin and its combination with hydroxypropyl-methylcellulose increases aqueous solubility of Δ 9-tetrahydrocannabinol. Life Sci 1998; 63: PL381–384
   PubMed Web of Science ®Google Scholar
• Hosseini A, Lattanzio F A, Williams P B, Tibbs D, Samudre S S, Allen R C. Chronic topical administration of WIN 55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects. Exp Eye Res 2006; 82: 753–759
   PubMedGoogle Scholar